Asia
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
Although promising, it’s still unclear if this would actually prevent infection in people.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
Biopharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.
Plurisitem Therapeutics’ PLX (Placental eXpanded) cells are showing promise as a therapy for patients with severe cases of COVID-19.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.
The collaboration for development and commercialization combines Esperion’s knowledge in lipid management and Otsuka’s extensive cardiovascular drug advancement and marketing in Japan.
At least some of the concern is that without greater funding and coordination, the companies won’t be able to buy sufficient raw materials, continue production of existing drugs and quickly scale up their capacity to meet the demand of new drugs and older therapies around the world.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
PRESS RELEASES